ArticleScientific reports2026
Liquid biopsy of plasma and urinary CfDNA differentiates glioma recurrence from radiation brain necrosis in preclinical models.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Clinical utility of liquid biopsy in distinguishing true progression from radiation necrosis and pseudoprogression in malignant brain tumor.Journal of neuro-oncology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
It is difficult to differentiate between glioma recurrence and radiation brain necrosis after radiotherapy in the clinic, but it is very important for patients. The purpose of this study is to observe the clinical significance of cell-free DNA (cfDNA) in the differential diagnosis between them based on liquid biopsy. The SD rats were used to establish a glioma recurrence model and a radiation brain necrosis model. The successful establishment of the two models was verified by MRI, IVFI, HE staining, immunofluorescence and immunohistochemistry. Then, the changes of cfDNA in the two models (B1-SINE in plasma and mtDNA in urine) were analyzed by qPCR. After ionizing particle irradiation, qPCR results showed that the level of mtDNA in urine increased significantly at the 6th week and reached the peak at the 8th week. The B1-SINE of plasma samples increased significantly at the 4th week of irradiation and reached the peak at the 8th week. From week 8 to week 16, when radiation necrosis occurred, the levels of mtDNA in urine and B1-SINE in plasma increased significantly (p < 0.01). In the glioma recurrence model, there was no significant difference in urinary mtDNA level and plasma B1-SINE level between the normal group and the sham surgery group (p > 0.05). These findings demonstrate that cfDNA liquid biopsy, represented by plasma B1-SINE and urinary mtDNA, holds significant clinical translational potential as an early differential diagnostic marker for radiation-induced brain necrosis and glioma recurrence, warranting further validation of its sensitivity and specificity through ROC analysis in clinical samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.